Gesynta Pharma’s drug candidates utilize a unique mechanism of action to reduce inflammation and pain. We are currently developing three drug candidates. One of the compounds has reached clinical phase II stage. A second one will start clinical testings in 2023. Read more about our drug development projects.
Development pipeline
Gesynta Pharma bases its R&D on research from the Karolinska Institutet. In a recently completed clinical phase II study, the most advanced drug candidate, GS-248, was evaluated with regards to its safety profile, its ability to inhibit mPGES-1, as well as its effect on Raynaud’s phenomenon and peripheral blood flow in systemic sclerosis patients. After treatment, no significant effects were seen compared to placebo in terms of symptomatic relief in patients with systemic sclerosis. For the first time in patients, however, the Phase II study confirmed the tolerability and safety profile, pharmacokinetics, and unique ability of GS-248 to inhibit mPGES-1 and thus modify prostaglandin profile. Collectively, the data strengthens the rationale to progress the development of the drug candidate in other chronic inflammatory diseases where mPGES-1 plays a key role.
Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.
Our executive team and board of directors hold vast experience in drug development, commercialization and company scale-up.
Systemic sclerosis is an autoimmune disease hallmarked by chronic inflammation in the body’s smallest blood vessels.
Endometriosis is a chronic, inflammatory, estrogen-dependent disease affecting millions of women worldwide.
